And are you comfortable with the cash-pay pricing structure, given that insurance reimbursement may not be available
semaglutide generally needs no dose adjustment Patients with kidney disease : Generally no dose adjustments needed for either medication, but monitoring is advised People with diabetes : Should be aware of the risk of diabetic retinopathy progression with rapid improvement in blood glucose control
Pregnancy outcomes after semaglutide exposure
Chief Financial Officer Executive Vice President, Pharmaceutical Development and Manufacturing Executive Vice President, Research Executive Vice President, Human Resources Chief Commercial Officer Chief Medical Officer Executive Vice President, Kite Executive Vice President, Corporate Affairs and General Counsel Yearly results *All sales figures and related information presented in this report are based on data from the previous calendar year
For new or worsening nephropathy, subcutaneous semaglutide did not significantly reduce the risk (RR 0.83, 95% CI 0.61 to 1.12), but it had a borderline significance compared with placebo (RR 0.81, 95% CI 0.66 to 1.00)